Press Releases - 2023-10-26

Date	Title	Company
26-Oct-2023	Serum Separation Gels Industry Set for a 5% CAGR Surge to US$12.39 Billion by 2032 \| FMI Insights	MARKITWIRED
26-Oct-2023	Peptide Receptor Radionuclide Therapy (PRRT) Industry Set to Surge to US$1.3 Billion by 2033 at an Impressive CAGR of 8.2% \| FMI	MARKITWIRED
26-Oct-2023	New Born Eye Imaging Systems Industry’s Growth Catalysts to Achieve US$ 374.3 Million by 2032 \| FMI Insights	MARKITWIRED
26-Oct-2023	Global Motorized Prosthesis Industry’s Ascension to a US$139.4 Million Valuation by 2032 with a Strong CAGR of 14.4%	MARKITWIRED
26-Oct-2023	Atrial Appendage Occluder Industry Soars to US$8.2 Billion by 2033: Unveiling the 23.6% CAGR Surge \| FMI Insights	MARKITWIRED
26-Oct-2023	Global Gel Implants Industry Set for US$1,760 Million by 2033 with a 3.8% CAGR, \| as Unveiled by FMI	MARKITWIRED
26-Oct-2023	Immunochemistry Analyzer Industry Anticipates US$ 72.69 Billion in 2032, Propelled by a 16% CAGR, \| FMI Reports	MARKITWIRED
26-Oct-2023	Exploring the 6.1% CAGR Outlook for the Global Nerve Monitoring Devices Industry through 2032 \| FMI Study	MARKITWIRED
26-Oct-2023	Phastar Offers Pro Bono Support to Medicines Development for Global Health	Phastar
26-Oct-2023	OGT and Intelliseq Launch NGS Reporting and Interpretation for All Myeloid Malignancy Panels	OGT
26-Oct-2023	IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader	IDP Pharma
26-Oct-2023	Quotient Sciences Announces Major Investment in Sterile Fill/Finish Capacity in Response to Increasing Industry Demand	Quotient Sciences
26-Oct-2023	MHRA Grants Conditional Marketing Authorisation for Tepkinly® ▼ (epcoritamab) as a Bispecific Treatment for Adults with Relapsed or Refractory DLBCL After Two or More Lines of Systemic Therapy	AbbVie
26-Oct-2023	IgNS and RxToolKit Announce Partnership to Provide Access to Continuing Education to RxToolKit Members	Newswire
26-Oct-2023	New NHS report shows increase in HRT prescriptions	NHSBSA
26-Oct-2023	GALDERMA PHASE III DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: FULL OLYMPIA 2 TRIAL RESULTS DEMONSTRATE NEMOLIZUMAB’S RAPID ONSET OF ACTION IN PRURIGO NODULARIS PATIENTS	Galderma
26-Oct-2023	AlzeCure presents disease-modifying data with NeuroRestore ACD856 at Alzheimer's conference CTAD	AlzeCure
26-Oct-2023	Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	Immunocore
26-Oct-2023	ALTURiX Introduces CEYESTO® Melatonin Oral Solution In The UK Featuring A Diverse Set Of Approved Indications - Two Of Which Are World-First	ALTURiX
26-Oct-2023	Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations	Mainz BioMed N.V.